Solitary pulmonary metastasis from lung cancer harboring EML4-ALK after a 15-year disease-free interval

Lung Cancer

Volumn 80, Issue 1, 2013, Pages 99-101

  Tomizawa, Kenji ^a,b   Ito, Simon ^a   Suda, Kenichi ^a   Fukui, Takayuki ^a   Usami, Noriyasu ^a   Hatooka, Shunzo ^a   Kuwano, Hiroyuki ^b   Yatabe, Yasushi ^a   Mitsudomi, Tetsuya ^c  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

EML4 ALK; Lung adenocarcinoma; Metachronous; Pulmonary metastasis

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTIBIOTIC AGENT; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CANCER SIZE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE FREE INTERVAL; FEVER; GENE REARRANGEMENT; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG METASTASIS; LYMPH NODE DISSECTION; MALE; MUCUS SECRETION; NEEDLE BIOPSY; PHYSICAL EXAMINATION; PNEUMONIA; PRIORITY JOURNAL; SOLITARY PULMONARY METASTASIS; THORAX PAIN; THORAX RADIOGRAPHY; TREATMENT REFUSAL; WEDGE RESECTION;

ADENOCARCINOMA; ADULT; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEINS, FUSION; TIME FACTORS;

EID: 84875253191     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.12.011     Document Type: Article

References (10)

1. Maeda R., Yoshida J., Hishida T., Aokage K., Nishimura M., Nishiwaki Y., et al. Late recurrence of non-small cell lung cancer more than 5 years after complete resection: incidence and clinical implications in patient follow-up. Chest 2010, 138:145-150.
2. Haraguchi S., Koizumi K., Hirata T., Hirai K., Mikami I., Kubokura H., et al. Surgical treatment of metachronous nonsmall cell lung cancer. Ann Thorac Cardiovasc Surg 2010, 16:319-325.
3. Martini N., Melamed M.R. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975, 70:606-612.
4. Tomizawa K., Suda K., Onozato R., Kosaka T., Endoh H., Sekido Y., et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer 2011, 74:139-144.
5. Takeuchi K., Choi Y.L., Soda M., Inamura K., Togashi Y., Hatano S., et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008, 14:6618-6624.
6. Choi Y.L., Takeuchi K., Soda M., Inamura K., Togashi Y., Hatano S., et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008, 68:4971-4976.
7. Sasaki T., Rodig S.J., Chirieac L.R., Janne P.A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010, 46:1773-1780.
8. Mitsudomi T., Yatabe Y., Koshikawa T., Hatooka S., Shinoda M., Suyama M., et al. Mutations of the P53 tumor suppressor gene as clonal marker for multiple primary lung cancers. J Thorac Cardiovasc Surg 1997, 114:354-360.
9. Girard N., Deshpande C., Azzoli C.G., Rusch V.W., Travis W.D., Ladanyi M., et al. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. Chest 2010, 137:46-52.
10. Pfeifer G.P., Denissenko M.F., Olivier M., Tretyakova N., Hecht S.S., Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002, 21:7435-7451.